Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13

References

• Sanchez A, Furberg H. Obesity paradox in patients with non-small cell lung cancer treated with immunotherapy. JAMA Oncol. 2020. DOI:10.1001/jamaoncol.2020.0634
   Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–454.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
   PubMed Web of Science ®Google Scholar
• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021 Feb;134:111111.
   PubMed Web of Science ®Google Scholar
• Sosa E, D’Souza G, Akhtar A, et al. Racial and socioeconomic disparities in lung cancer screening in the United States: a systematic review. CA Cancer J Clin. 2021;71:299–314.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Lu Y, Lu H, et al. Development of a survival prognostic model for non-small cell lung cancer. Front Oncol. 2020;10:362.
   PubMedGoogle Scholar
• Lu C, Dong XR, Zhao J, et al. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. J Hematol Oncol. 2020;13:37.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.
   PubMed Web of Science ®Google Scholar
• Jarosz-Biej M, Smolarczyk R, Cichon T, et al. Tumor microenvironment as a “game changer” in cancer radiotherapy. Int J Mol Sci. 2019;20. DOI:10.3390/ijms20133212
   PubMed Web of Science ®Google Scholar
• Albini A, Bruno A, Noonan DM, et al. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol. 2018;9:527.
   PubMed Web of Science ®Google Scholar
• Walton EL. Radiotherapy and the tumor microenvironment: the “macro” picture. Biomed J. 2017;40:185–188.
   PubMed Web of Science ®Google Scholar
• Fang J, Li X, Ma D, et al. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC Cancer. 2017 May 26;17(1):375.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu S, Yang Y, et al. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer. Biomed Pharmacother. 2017 Nov;95:55–61.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Z, Gao A, et al. The prognostic landscape of tumor-infiltrating immune cells in cervical cancer. Biomed Pharmacother. 2019 Dec;120:109444.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang T, Kang Z, et al. Tumor-infiltrating immune cells act as a marker for prognosis in colorectal cancer. Front Immunol. 2019;10:2368.
   PubMed Web of Science ®Google Scholar
• Li F, Guo H, Wang Y, et al. Profiles of tumor-infiltrating immune cells and prognostic genes associated with the microenvironment of bladder cancer. Int Immunopharmacol. 2020;85:106641.
   PubMed Web of Science ®Google Scholar
• Wang Z, Xu H, Zhu L, et al. Establishment and evaluation of a 6-gene survival risk assessment model related to lung adenocarcinoma microenvironment. Biomed Res Int. 2020;2020:6472153.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Caglevic C, Santarpia M, et al. Immunotherapy in NSCLC: a promising and revolutionary weapon. Adv Exp Med Biol. 2017;995:97–125.
   PubMed Web of Science ®Google Scholar
• Bianco A, Malapelle U, Rocco D, et al. Targeting immune checkpoints in non-small cell lung cancer. Curr Opin Pharmacol. 2018;40:46–50.
   PubMed Web of Science ®Google Scholar
• Soo RA, Lim SM, Syn NL, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions. Lung Cancer. 2018;115:12–20.
   PubMed Web of Science ®Google Scholar
• Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer–recent advances and future perspectives. Int J Cancer. 2016;138:2549–2561.
   PubMed Web of Science ®Google Scholar
• Franzén O, Gan LM, Björkegren JLM. PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. Database. 2019;2019. DOI:10.1093/database/baz046
   PubMedGoogle Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2.
   PubMed Web of Science ®Google Scholar
• Liao Y, Wang Y, Cheng M, et al. Weighted gene coexpression network analysis of features that control cancer stem cells reveals prognostic biomarkers in lung adenocarcinoma. Front Genet. 2020;11:311.
   PubMed Web of Science ®Google Scholar
• Liao Y, Xiao H, Cheng M, et al. Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in lung squamous cell carcinoma. Front Genet. 2020;11:427.
   PubMed Web of Science ®Google Scholar
• Ravindran S, Rasool S, Maccalli C. The cross talk between cancer stem cells/cancer initiating cells and tumor microenvironment: the missing piece of the puzzle for the efficient targeting of these cells with immunotherapy. Cancer Microenviron. 2019;12:133–148.
   PubMed Web of Science ®Google Scholar
• Belli C, Trapani D, Viale G, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22–32.
   PubMed Web of Science ®Google Scholar
• Qu Y, Dou B, Tan H, et al. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol Cancer. 2019;18:69.
   PubMed Web of Science ®Google Scholar
• Kavunja HW, Lang S, Sungsuwan S, et al. Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice. Cancer Immunol Immunother. 2017;66:451–460.
   PubMed Web of Science ®Google Scholar
• Dou Y, Liu Y, Zhao F, et al. Radiation-responsive scintillating nanotheranostics for reduced hypoxic radioresistance under ROS/NO-mediated tumor microenvironment regulation. Theranostics. 2018;8:5870–5889.
   PubMed Web of Science ®Google Scholar
• Larionova I, Cherdyntseva N, Liu T, et al. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology. 2019;8:1596004.
   PubMed Web of Science ®Google Scholar
• Thepmalee C, Panya A, Junking M, et al. Inhibition of IL-10 and TGF-beta receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells. Hum Vaccin Immunother. 2018;14:1423–1431.
   PubMed Web of Science ®Google Scholar
• Dong ZY, Zhang C, Li YF, et al. Genetic and immune profiles of solid predominant lung adenocarcinoma reveal potential immunotherapeutic strategies. J Thorac Oncol. 2018;13:85–96.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, N.Y.). 2015;348:74–80.
   PubMed Web of Science ®Google Scholar
• Djenidi F, Adam J, Goubar A, et al. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol (Baltimore, Md: 1950). 2015;194:3475–3486.
   PubMed Web of Science ®Google Scholar
• Hao J, Wang H, Song L, et al. Infiltration of CD8(+) FOXP3(+) T cells, CD8(+) T cells, and FOXP3(+) T cells in non-small cell lung cancer microenvironment. Int J Clin Exp Pathol. 2020;13:880–888.
   PubMed Web of Science ®Google Scholar
• Yang B, Rao W, Luo H, et al. Relapse-related molecular signature in early-stage lung adenocarcinomas based on BER, STING pathway, and TILs. Cancer Sci. 2020. DOI:10.1111/cas.14570
   Web of Science ®Google Scholar
• Bi KW, Wei XG, Qin XX, et al. Potential to be a prognostic factor for lung adenocarcinoma and an indicator for tumor microenvironment remodeling: a study based on TCGA data mining. Front Oncol. 2020;10:424.
   PubMed Web of Science ®Google Scholar
• Song Q, Shang J, Yang Z, et al. Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma. J Transl Med. 2019;17:70.
   PubMed Web of Science ®Google Scholar
• Bellefeuille SD, Molle CM, Gendron FP. Reviewing the role of P2Y receptors in specific gastrointestinal cancers. Purinergic signaling. 2019;15:451–463.
   PubMed Web of Science ®Google Scholar
• Burnstock G, Knight GE. Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol. 2004;240:31–304.
   PubMed Web of Science ®Google Scholar
• Hevia MJ, Castro P, Pinto K, et al. Differential effects of purinergic signaling in gastric cancer-derived cells through P2Y and P2X receptors. Front Pharmacol. 2019;10:612.
   PubMed Web of Science ®Google Scholar
• Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2017;36:293–303.
   PubMed Web of Science ®Google Scholar
• Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20. DOI:10.3390/ijms20040840
   PubMed Web of Science ®Google Scholar
• Burnstock G, Jacobson KA, Christofi FL. Purinergic drug targets for gastrointestinal disorders. Curr Opin Pharmacol. 2017;37:131–141.
   PubMed Web of Science ®Google Scholar
• Tan Q, Huang Y, Deng K, et al. Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment. J Cell Biochem. 2020. DOI:10.1002/jcb.29675
   Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50:924–940.
   PubMed Web of Science ®Google Scholar